Peer-Reviewed Publication
J Allergy Clin Immunol Glob2026;5(6):100771.November 1, 2026Journal Article
Consistent adherence to biologic therapies is critical for improving outcomes in asthma.
Njira L Lugogo1, Brian Modena2, Justin Kwiatek3, Jiaxuan Wang4, Peter Howarth5, Riyad Al-Lehebi6,7, Anna Vichiendilokkul8, Urvee Karsanji9, Jeremiah Hwee10, Gerald Smith4, Riley Geason11, Arijita Deb12, Rafael Alfonso-Cristancho12
1Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Mich.
2Modena Health, La Jolla, Calif.
3Medical Affairs, GSK, Upper Providence, Pa.
4Cytel, Inc, Vancouver, British Columbia, Canada.
5Global Medical Affairs, Specialty Care, GSK, London, United Kingdom.
6Department of Pulmonology, King Fahad Medical City, Riyadh, Saudi Arabia.
7College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
8Global Medical Affairs, GSK, Collegeville, Pa.
9Real World Biostatistics, GSK, London, United Kingdom.
10Global Epidemiology, GSK, Mississauga, Ontario, Canada.
11Real World Evidence, Cytel Inc, Boston, Mass.
12Global Real-World Evidence & Health Outcomes Research, GSK, Collegeville, Pa.
Abstract
BACKGROUND: Evidence on real-world adherence to asthma biologic therapies and the relevance to clinical outcomes in asthma is limited.
OBJECTIVE: We sought to evaluate biologic use patterns and the relationships between adherence, clinical, and health care resource utilization (HCRU) outcomes and economic burden in patients with asthma.
METHODS: This was a retrospective observational study using…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans